Home » Newsletters » BioWorld

BioWorld

Oct. 1, 1997

View Archived Issues

Other News To Note

Bristol-Myers To Pay ICAgen $75M For Heart Drugs

Two Recombinant Fertility Drugs Cleared By FDA For Marketing

PTEN Oncogene Targets Many Tumors, Prefers Uterine Cancer

Regeneron, P&G Expand Deal To Include Obesity For $15M

Genetic, Health Care Revolutions Leave Policymakers Uneasy

Genzyme Transgenics Signs $13M TransGeneric Protein Deal

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for December 17, 2024.
Second insulin receptor offers new therapeutic avenues
BioWorld Science
Investigators at the Helmholtz Institute have shown that inceptor, an inhibitor of the insulin signaling pathway, acted by binding insulin and targeting it for...
Drug duo to Repare lack in gyno cancers? Phase I shows promise
BioWorld
Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...
Mechanism underlying so-called idiopathic autism inception unveiled
BioWorld Science
Investigators at the Institute for Research in Biomedicine (IRB Barcelona) have unraveled how and why the absence of a neuronal microexon in cytoplasmic...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.